Royalty Pharma plc (RPRX) income statement
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.67−0.01 (-0.01%)
Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –
Royalty Pharma plc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 59.6%
- Net margin
- 32.1%
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 2.80
- Debt to equity
- –
- Debt to assets
- 45.2%
- Cash to current liabilities
- 128.7%
Valuation
- P/E ratio
- 39.0
- Price to sales
- 15.57
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?